Organon & Co. (NYSE: OGN) Stock Competitors & Peer Comparison

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while LLY trades at $1,231.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas LLY's P/E ratio is 39.10. In terms of profitability, OGN's ROE is +0.23%, compared to LLY's ROE of +0.93%. Regarding short-term risk, OGN is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for OGN.Check LLY's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, JNJ has a market cap of 630.6B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while JNJ trades at $261.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas JNJ's P/E ratio is 24.39. In terms of profitability, OGN's ROE is +0.23%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, OGN is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for OGN.Check JNJ's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, ABBV has a market cap of 437.9B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while ABBV trades at $247.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas ABBV's P/E ratio is 24.32. In terms of profitability, OGN's ROE is +0.23%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, OGN is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for OGN.Check ABBV's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, MRK has a market cap of 323.3B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while MRK trades at $130.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas MRK's P/E ratio is 40.78. In terms of profitability, OGN's ROE is +0.23%, compared to MRK's ROE of +0.07%. Regarding short-term risk, OGN is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for OGN.Check MRK's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, NVS has a market cap of 298B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while NVS trades at $156.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas NVS's P/E ratio is 18.04. In terms of profitability, OGN's ROE is +0.23%, compared to NVS's ROE of +0.30%. Regarding short-term risk, OGN is less volatile compared to NVS. This indicates lower risk in terms of short-term price fluctuations for OGN.Check NVS's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, AZN has a market cap of 251.1B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while AZN trades at $161.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas AZN's P/E ratio is 17.48. In terms of profitability, OGN's ROE is +0.23%, compared to AZN's ROE of +0.22%. Regarding short-term risk, OGN is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for OGN.Check AZN's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while AMGN trades at $417.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas AMGN's P/E ratio is 18.37. In terms of profitability, OGN's ROE is +0.23%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, OGN is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for OGN.Check AMGN's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, NVO has a market cap of 212B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while NVO trades at $47.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas NVO's P/E ratio is 11.87. In terms of profitability, OGN's ROE is +0.23%, compared to NVO's ROE of +0.59%. Regarding short-term risk, OGN is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for OGN.Check NVO's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, GILD has a market cap of 165.2B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while GILD trades at $133.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas GILD's P/E ratio is -341.18. In terms of profitability, OGN's ROE is +0.23%, compared to GILD's ROE of -0.16%. Regarding short-term risk, OGN is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for OGN.Check GILD's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, PFE has a market cap of 154.2B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while PFE trades at $27.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas PFE's P/E ratio is 8.87. In terms of profitability, OGN's ROE is +0.23%, compared to PFE's ROE of +0.05%. Regarding short-term risk, OGN is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for OGN.Check PFE's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, BMY has a market cap of 132.5B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while BMY trades at $64.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas BMY's P/E ratio is 10.94. In terms of profitability, OGN's ROE is +0.23%, compared to BMY's ROE of +0.47%. Regarding short-term risk, OGN is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for OGN.Check BMY's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, GSK has a market cap of 104.6B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while GSK trades at $52.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas GSK's P/E ratio is 11.27. In terms of profitability, OGN's ROE is +0.23%, compared to GSK's ROE of +0.24%. Regarding short-term risk, OGN is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for OGN.Check GSK's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while SNY trades at $43.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas SNY's P/E ratio is 9.47. In terms of profitability, OGN's ROE is +0.23%, compared to SNY's ROE of +0.06%. Regarding short-term risk, OGN is less volatile compared to SNY. This indicates lower risk in terms of short-term price fluctuations for OGN.Check SNY's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, ZTS has a market cap of 31.4B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while ZTS trades at $74.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas ZTS's P/E ratio is 11.37. In terms of profitability, OGN's ROE is +0.23%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, OGN is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for OGN.Check ZTS's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, BIIB has a market cap of 30.6B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while BIIB trades at $207.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas BIIB's P/E ratio is 13.08. In terms of profitability, OGN's ROE is +0.23%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, OGN is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for OGN.Check BIIB's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas HZNP's P/E ratio is 61.86. In terms of profitability, OGN's ROE is +0.23%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, OGN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for OGN.Check HZNP's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while GRFS trades at $8.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas GRFS's P/E ratio is 9.25. In terms of profitability, OGN's ROE is +0.23%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, OGN is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for OGN.Check GRFS's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, CELG-RI has a market cap of 206.3M. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while CELG-RI trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, OGN's ROE is +0.23%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, OGN is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for OGN.Check CELG-RI's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, CTOR has a market cap of 70.2M. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while CTOR trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas CTOR's P/E ratio is -1.61. In terms of profitability, OGN's ROE is +0.23%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, OGN is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for OGN.Check CTOR's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while SCLXW trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, OGN's ROE is +0.23%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, OGN is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for OGN.Check SCLXW's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, SCLX has a market cap of 56.8M. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while SCLX trades at $6.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas SCLX's P/E ratio is -0.17. In terms of profitability, OGN's ROE is +0.23%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, OGN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for OGN.Check SCLX's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, MIRA has a market cap of 32.2M. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while MIRA trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas MIRA's P/E ratio is -0.53. In terms of profitability, OGN's ROE is +0.23%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, OGN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for OGN.Check MIRA's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, OGN's ROE is +0.23%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, OGN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for OGN.Check BDSIW's competition here

Organon & Co. (NYSE: OGN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OGN stands at 3.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, OGN is priced at $13.62 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OGN currently has a P/E ratio of 4.07, whereas CRXT's P/E ratio is -0.02. In terms of profitability, OGN's ROE is +0.23%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, OGN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for OGN.Check CRXT's competition here